Daniel E. Casey

6.4k total citations · 1 hit paper
73 papers, 4.2k citations indexed

About

Daniel E. Casey is a scholar working on Psychiatry and Mental health, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Daniel E. Casey has authored 73 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Psychiatry and Mental health, 21 papers in Neurology and 19 papers in Cellular and Molecular Neuroscience. Recurrent topics in Daniel E. Casey's work include Schizophrenia research and treatment (45 papers), Epilepsy research and treatment (15 papers) and Bipolar Disorder and Treatment (14 papers). Daniel E. Casey is often cited by papers focused on Schizophrenia research and treatment (45 papers), Epilepsy research and treatment (15 papers) and Bipolar Disorder and Treatment (14 papers). Daniel E. Casey collaborates with scholars based in United States, Denmark and Belgium. Daniel E. Casey's co-authors include Charles H. Hennekens, Danielle Hollar, Jes Gerlach, Stevin H. Zorn, David B. Allison, Duane Denney, Charles K. Meshul, William F. Hoffman, David G. Daniel and Patricia Wozniak and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Biological Psychiatry.

In The Last Decade

Daniel E. Casey

72 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Schizophrenia and increased risks of cardiovascular disease

2005 861 citations Charles H. Hennekens, Danielle Hollar et al. American Heart Journal profile →

Peers

Countries citing papers authored by Daniel E. Casey

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Casey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Casey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Casey more than expected).

Fields of papers citing papers by Daniel E. Casey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Casey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Casey. The network helps show where Daniel E. Casey may publish in the future.

Co-authorship network of co-authors of Daniel E. Casey

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Casey. A scholar is included among the top collaborators of Daniel E. Casey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Casey. Daniel E. Casey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization 2015 ·Schizophrenia Research ·Henry A. Nasrallah, Philip D. Harvey, Daniel E. Casey, (unknown), James I. Hudson, Laura Julián, Ellen Lentz, Keith H. Nuechterlein, Diana O. Perkins, (unknown), (unknown), Lonnie R. Snowden, Rajiv Tandon, Cenk Tek, Dawn I. Velligan, Sophia Vinogradov, Cedric O’Gorman	19
2	A Double-Blind Randomized Trial of Mood Stabilizer Augmentation Using Lamotrigine and Valproate for Patients With Schizophrenia Who Are Stabilized and Partially Responsive 2009 ·Journal of Clinical Psychopharmacology ·Ira D. Glick, Jackie Bosch, Daniel E. Casey	24
3	Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia 2008 ·Neuropsychopharmacology ·Daniel E. Casey, David G. Daniel, Carol A. Tamminga, John M. Kane, Tram Tran-Johnson, Patricia Wozniak, Walid Abi‐Saab, Jeff Baker, Laura Redden, Nicholas J. Greco, Mario Saltarelli	41
4	Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study 2008 ·Psychopharmacology ·Daniel E. Casey, (unknown), (unknown), (unknown)	49
5	Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo 2007 ·The Journal of Clinical Psychiatry ·Gilbert L’Italien, Daniel E. Casey	61
6	Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms 2006 ·CNS Spectrums ·Daniel E. Casey	49
7	Schizophrenia and increased risks of cardiovascular disease breakdown → 2005 ·American Heart Journal ·Charles H. Hennekens, (unknown), Danielle Hollar, Daniel E. Casey	861
8	Metabolic issues and cardiovascular disease in patients with psychiatric disorders 2005 ·PubMed ·Daniel E. Casey	164
9	Metabolic Effects of Treatment With Atypical Antipsychotics 2004 ·The Journal of Clinical Psychiatry ·John M. Kane, (unknown), Daniel E. Casey, Christoph U. Correll, Alan J. Gelenberg, Samuel Klein, John W. Newcomer	58
10	Schizophrenia, Metabolic Disorders, and Cardiovascular Disease 2004 ·The Journal of Clinical Psychiatry ·Daniel E. Casey, Dan Haupt, John W. Newcomer, David C. Henderson, Michael J. Sernyak, Michael Davidson, Jean‐Pierre Lindenmayer, Steven V. Manoukian, Mary Ann Banerji, Harold E. Lebovitz	2
11	Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia 2003 ·Neuropsychopharmacology ·Daniel E. Casey, David G. Daniel, Adel Wassef, Katherine Tracy, Patricia Wozniak, Kenneth W. Sommerville	165
12	Effect of a Novel Potential Atypical Antipsychotic Drug, Y-931, in Producing Dystonia in Cebus Monkeys 2003 ·Journal of Pharmacological Sciences ·(unknown), (unknown), (unknown), Hiroshi Tanaka, Daniel E. Casey	2
13	Changes in body mass index for individuals with and without schizophrenia, 1987–1996 2002 ·Schizophrenia Research ·Peter Homel, Daniel E. Casey, David B. Allison	118
14	The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates 2001 ·Psychopharmacology ·Daniel E. Casey, Jacques Bruhwyler, J. Delarge, Joseph Géczy, (unknown)	11
15	Barriers to progress-the impact of tolerability problems 2001 ·International Clinical Psychopharmacology ·Daniel E. Casey	17
16	Introduction. Antipsychotic standard of care: Redefining the definition of atypical antipsychotics 2000 ·The Journal of Clinical Psychiatry ·Daniel E. Casey	2
17	Introduction: Update on Tardive Dyskinesia 2000 ·The Journal of Clinical Psychiatry ·Daniel E. Casey	1
18	Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? 1997 ·International Clinical Psychopharmacology ·Daniel E. Casey	19
19	Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment 1989 ·Brain Research ·Charles K. Meshul, Daniel E. Casey	103
20	Behavioral aspects of GABA-dopamine interrelationships in the monkey 1980 ·Brain Research Bulletin ·Daniel E. Casey, Jes Gerlach, Erik Christensson	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact